Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Domati

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Diagnostics (Basel, Switzerland)|April 3, 2021
The Prognostic and Predictive Role of Somatic <i>BRCA</i> Mutations in Ovarian Cancer: Results from a Multicenter Cohort StudyAngela Toss, Claudia Piombino, Elena Tenedini, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
NPJ Breast Cancer|August 2, 2024
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian studyRoberta Scafetta, Raffaella Troiano, Carla Gullotta, et al.
The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Diagnostics (Basel, Switzerland)|April 3, 2021
The Prognostic and Predictive Role of Somatic <i>BRCA</i> Mutations in Ovarian Cancer: Results from a Multicenter Cohort StudyAngela Toss, Claudia Piombino, Elena Tenedini, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
NPJ Breast Cancer|August 2, 2024
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian studyRoberta Scafetta, Raffaella Troiano, Carla Gullotta, et al.
The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Pageof 4